Glaukos to Showcase Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Glaukos Corporation (NYSE: GKOS), a leading innovator in ophthalmic pharmaceuticals and medical devices, has announced its prominent participation in the upcoming American Society of Cataract and Refractive Surgery Annual Meeting 2026, scheduled to take place from April 10 to April 13, 2026, in Washington, D.C.. The company, widely recognized for its focus on advancing therapies for glaucoma, corneal disorders, and retinal diseases, will showcase its latest technologies and clinical insights across multiple scientific sessions and educational programs during the event.
As one of the most influential gatherings in the ophthalmic field, the ASCRS Annual Meeting attracts thousands of anterior segment surgeons, clinicians, researchers, and industry leaders from around the world. Within this highly collaborative environment, Glaukos aims to highlight its expanding portfolio of innovative treatment solutions designed to address unmet needs in eye care. The company will also host an exhibit at booth #407, where attendees can explore its technologies and engage directly with clinical and commercial representatives.
A key highlight of Glaukos’ presence at the meeting is its sponsorship of a dedicated educational symposium organized in collaboration with EyeWorld. Titled “Introducing Epioxa™, the first and only FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment,” the symposium will take place on Friday, April 10, 2026, from 12:00 to 1:00 p.m. ET at the Walter E. Washington Convention Center. This session is expected to draw significant interest as it introduces Epioxa™, a groundbreaking advancement in the management of keratoconus and other corneal ectatic disorders.
The symposium will feature a distinguished panel of experts, including Brandon D. Ayres, who will serve as moderator, alongside Kenneth A. Beckman, Maanasa Indaram, and Matt Jensen. These faculty members will provide in-depth insights into the clinical benefits, mechanism of action, and real-world implications of Epioxa™, which represents a significant shift toward less invasive corneal cross-linking approaches. By preserving the corneal epithelium and utilizing oxygen-enriched technology, the treatment aims to enhance patient comfort while maintaining therapeutic efficacy.
Beyond the symposium, Glaukos will contribute extensively to the scientific program through a series of oral presentations focused on glaucoma and corneal health. These sessions will showcase new clinical data, emerging technologies, and evolving treatment paradigms that reflect the company’s commitment to innovation and evidence-based medicine.
On Saturday, April 11, 2026, Arkadiy Yadgarov will present findings on the 12-month outcomes of standalone third-generation trabecular micro-bypass stents in patients with open-angle glaucoma. This presentation will explore the long-term safety and efficacy of minimally invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure while minimizing surgical risk.
Later that day, Michael B. Raizman will deliver a presentation reviewing the design and clinical development plan for a novel keratoconus screening device. Early detection of keratoconus remains a critical challenge in ophthalmology, and innovations in screening technology could play a vital role in improving patient outcomes through earlier intervention.
The scientific program continues on Sunday, April 12, 2026, with additional presentations highlighting advancements in glaucoma treatment. Jasmin Kaur and Savak Teymoorian will present 12-month single-center outcomes of a travoprost intracameral implant in patients with open-angle glaucoma or ocular hypertension. This sustained-release drug delivery approach represents a promising alternative to traditional topical therapies, potentially improving patient adherence and long-term disease control.
Later that afternoon, Lisa K. Feulner will discuss real-world outcomes associated with combining trabecular micro-bypass stents with either an intracameral travoprost implant or cataract surgery. Combination therapies are increasingly being explored as a means to enhance treatment efficacy and streamline patient care, particularly in individuals with coexisting ocular conditions.
In addition to these oral presentations, Glaukos-supported research will also be featured in several on-demand poster sessions. These posters provide further insight into the safety, efficacy, and durability of the company’s technologies across diverse clinical settings.
Among the contributors, Kenneth A. Beckman will present data on the persistence of treatment effects following epithelium-on corneal collagen cross-linking in patients with keratoconus. This research underscores the potential long-term benefits of Epioxa™ and similar approaches.
John P. Berdahl will share findings on the safety and efficacy of a 75 mcg travoprost intracameral implant when used in combination with a trabecular micro-bypass system, with outcomes evaluated over a three-month period. Similarly, Christine N. Funke will present one-month outcomes of combining third-generation micro-bypass stents with a travoprost implant, with or without concurrent cataract surgery.
Additional contributions include research by Steven R. Sarkisian Jr., who will present early outcomes from an open-label cohort evaluating a second-generation travoprost intracameral implant, and Zachary D. Vest, who will report two-year outcomes following third-generation trabecular micro-bypass procedures performed in conjunction with phacoemulsification.
Collectively, these presentations and posters highlight the breadth and depth of Glaukos’ research and development efforts, spanning both device-based and pharmaceutical innovations. The company’s integrated approach—combining micro-invasive surgical devices with sustained-release drug delivery systems—reflects a broader trend in ophthalmology toward more personalized and efficient treatment strategies.
The ASCRS Annual Meeting serves as a vital platform for the exchange of scientific knowledge and clinical expertise, enabling healthcare professionals to stay at the forefront of advancements in eye care. While the educational content presented at the meeting is curated by the ASCRS program committee and does not constitute endorsement of specific products or technologies, the inclusion of Glaukos’ innovations within the program underscores their growing relevance in the field.
As Glaukos continues to expand its portfolio and invest in cutting-edge research, its participation in high-profile events like the ASCRS Annual Meeting reinforces its position as a key player in the global ophthalmic industry. By fostering collaboration with clinicians and researchers, the company aims to accelerate the development and adoption of transformative therapies that improve vision outcomes and quality of life for patients worldwide.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time.
Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
About Epioxa HD / Epioxa
Indication: EPIOXA™ HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.
Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.
Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.
Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.
Adverse Reactions:The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.
About iDose® TR (U.S.)
iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm’s canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for 24/7 release of medication.
Indication for Use: iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
Dosage and Administration: For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.
Contraindications: iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.
Warnings and Precautions: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.
Adverse Reactions: In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.
About iStent infinite® Trabecular Micro-Bypass System (U.S.)
Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.
Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.
MRI Information:The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.
Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.
Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%).
Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.
Source Link:https://www.businesswire.com/
